Prestige Healthcare (PBH) Q2 2027 Earnings Call Transcript
Prestige Healthcare (PBH) reported Q2 2027 earnings, with revenue up 23% to $336.3M, driven by acquisitions and organic growth. Adjusted EPS rose 6% to $1.13. The company integrated Breathe Right and LaCorium, expecting long-term growth. eCommerce sales grew mid-teens, with investments in digital media and content.
How this was made

The 30-second read
Why it matters
The earnings release confirms successful integration and revenue contribution from the new brands, reinforcing the company's growth strategy.
Market read
First‑time earnings disclosure with strong top‑line growth, likely to move PBH stock and influence the consumer health sector.
What to watch
The modest decline in adjusted free cash flow and higher interest expense could limit near‑term cash generation.
Background
Prestige Healthcare recently completed the Breathe Right and LaCorium acquisitions, integrating them into its portfolio.
Ticker impact
Q2 2027 earnings call disclosed revenue of $336.3M (+22.7% YoY) and adjusted EPS of $1.13, marking the first public release of these figures.
likely upward pressure as market prices in the earnings beat and improved outlook.
The company reported better-than-expected top line and EPS, and announced debt reduction plans, which typically support a positive price reaction.
Market effects
Highlights growth potential in consumer health and over‑the‑counter therapeutic brands, possibly boosting peer valuations.
Strong performance in North America and international segments may lift related health‑care stocks.
Adds to the broader narrative of resilient consumer health demand amid inflationary pressures.
Counterpoint
If integration costs or debt servicing pressures materialize, the stock could face downside despite the earnings beat.
Key entities
- CompanyPrestige Healthcare
US‑listed consumer health company reporting Q2 2027 results.


